These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26899665)

  • 1. Brivaracetam: First Global Approval.
    Markham A
    Drugs; 2016 Mar; 76(4):517-22. PubMed ID: 26899665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brivaracetam for the treatment of epilepsy.
    Klein P; Tyrlikova I; Brazdil M; Rektor I
    Expert Opin Pharmacother; 2016; 17(2):283-95. PubMed ID: 26760311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of brivaracetam: a new drug to treat epilepsy.
    Milovanović JR; Janković SM; Pejčić A; Milosavljević M; Opančina V; Radonjić V; Protrka Z; Kostić M
    Expert Opin Pharmacother; 2017 Sep; 18(13):1381-1389. PubMed ID: 28737479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brivaracetam: An Adjunctive Treatment for Partial-Onset Seizures.
    Kappes JA; Hayes WJ; Strain JD; Farver DK
    J Clin Pharmacol; 2017 Jul; 57(7):811-817. PubMed ID: 28394442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy.
    Klein P; Bourikas D
    Adv Ther; 2024 Jul; 41(7):2682-2699. PubMed ID: 38811492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brivaracetam: new compound approved for the treatment of epilepsy.
    Zaccara G
    Drugs Today (Barc); 2016 Apr; 52(4):219-27. PubMed ID: 27252986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.
    Hoy SM
    CNS Drugs; 2016 Aug; 30(8):761-72. PubMed ID: 27503181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brivaracetam for the treatment of epilepsy in adults.
    Mula M
    Expert Rev Neurother; 2014 Apr; 14(4):361-5. PubMed ID: 24625006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brivaracetam UCB.
    Malawska B; Kulig K
    Curr Opin Investig Drugs; 2005 Jul; 6(7):740-6. PubMed ID: 16044671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brivaracetam: a new drug in development for epilepsy and neuropathic pain.
    Malawska B; Kulig K
    Expert Opin Investig Drugs; 2008 Mar; 17(3):361-9. PubMed ID: 18321235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.
    Pollard JR
    Curr Opin Investig Drugs; 2008 Jan; 9(1):101-7. PubMed ID: 18183537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
    Mumoli L; Palleria C; Gasparini S; Citraro R; Labate A; Ferlazzo E; Gambardella A; De Sarro G; Russo E
    Drug Des Devel Ther; 2015; 9():5719-25. PubMed ID: 26543353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.
    Schoemaker R; Wade JR; Stockis A
    J Clin Pharmacol; 2016 Dec; 56(12):1591-1602. PubMed ID: 27146213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.
    Russo E; Citraro R; Mula M
    Expert Opin Drug Discov; 2017 Nov; 12(11):1169-1178. PubMed ID: 28829199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Brivaracetam in the treatment of patients with epilepsy].
    Karlov VA; Vlasov PN; Zhidkova IA; Kissin MY; Lebedeva AV; Lipatova LV; Mkrtchyan VR; Mukhin KY; Rudakova IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9. Vyp. 2):55-62. PubMed ID: 29213040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.